Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Chemotherapy + LDRT in Extensive-Stage SCLC
NCT06610734Phase 2Recruiting
- Sponsor
- Sichuan University
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of adebrelimab in small cell lung cancer (SCLC) (2 arms), sponsored by Sichuan University. Primary endpoint: Overall Survival at 36 months. Started Dec 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06610734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06610734.